Stock Screener App

無料 -

インストール

4.185

4.95% 0.205

Perspective Therapeutics Inc (CATX)

概要ニュース株価時系列ディスカッション予測株式分割

Perspective Therapeutics Inc (CATX) 最新ニュース

A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15 - Moomoo

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo

Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo

Perspective Therapeutics Presents Positive Clinical Data for [212Pb] Radiopharmaceuticals in Melanoma, Neuroendocrine, and Solid Tumors at ASCO 2026 - Minichart

CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill

Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO - Stock Titan

Perspective Therapeutics, Inc. Reports Positive Updates on Clinical Programs at ASCO 2026, Highlighting Efficacy and Safety of [212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359 - Quiver Quantitative

Early melanoma trial sees tumor responses in hard-to-treat patients - Stock Titan

UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - MSN

Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

Earnings Preview: CATX to Report Financial Results Post-market on May 11 - Moomoo

CATX: VMT-α-NET shows high efficacy and safety, with phase III readiness and broad pipeline progress - TradingView

CATX News | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill

Perspective Therapeutics doses first patients in two trial cohorts By Investing.com - Investing.com Australia

Perspective Therapeutics doses first patients in two trial cohorts - Investing.com UK

Perspective Therapeutics (CATX) Begins Patient Dosing in New Cli - GuruFocus

Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors - marketscreener.com

Perspective Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2a Studies for [212Pb]VMT-α-NET and [212Pb]PSV359 in Neuroendocrine and Solid Tumors - Quiver Quantitative

Two cancer radiopharmaceuticals start dosing patients in early trials - Stock Titan

CATX Should I Buy - Intellectia AI

Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail

CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill

Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX) - Stock Titan

RBC Capital reiterates Outperform on Perspective Therapeutics stock By Investing.com - Investing.com Nigeria

RBC Capital reiterates Outperform on Perspective Therapeutics stock - Investing.com

MSN Money - MSN

Working capital per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView

Perspective Therapeutics earnings beat by $0.05, revenue fell short of estimates - Investing.com Canada

Perspective Therapeutics (NYSEARCA:CATX) Posts Mixed Q1 2026 Results, EPS Beat and Revenue Miss - ChartMill

Perspective Therapeutics 1Q Loss/Shr 25c >CATX - Moomoo

Is Perspective Therapeutics (CATX) Attractively Valued After Q1 - GuruFocus

Perspective Therapeutics: Q1 Earnings Snapshot - KTVB

Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances - TipRanks

Perspective Therapeutics Q1 net loss widens as grant revenue drops - TradingView

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results - The Manila Times

[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Perspective Therapeutics (NYSE: CATX) posts Q1 loss, cash runway to late 2027 - Stock Titan

Perspective Therapeutics: $271M cash to advance 3 cancer trials - Stock Titan

Number of shareholders of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView

Number of shareholders of Perspective Therapeutics, Inc. – DUS:AAJ0 - TradingView

Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Analysts - MarketBeat

Transcript : Perspective Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - Moomoo

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX) - The Globe and Mail

Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler - The Globe and Mail

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $14 - 富途牛牛

Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Perspective Therapeutics Advances 212Pb Radioligand Therapy for Targeted Oncology with Regional Manufacturing and Theranostic Approach 1245 - Minichart

Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst CallSlideshow (NYSE:CATX) 2026-05-04 - Seeking Alpha

Perspective Therapeutics (CATX) unveils 212Pb theranostic pipeline and manufacturing strategy - Stock Titan

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field - Seeking Alpha

ZBH

$85.11

0.32%

STE

$215.00

2.22%

PHG

$27.12

0.22%

DXCM

$71.14

0.17%

GEHC

$63.91

0.23%

EW

$86.29

3.64%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | ロイターで開く